Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177406 · ClinicalTrials.gov registry record
Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,839
- Enrollment target
NCT05177406: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05177406 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,839 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05177406 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,839 participants
- Enrollment target
Study Summary
The proposed study is a retrospective, non-interventional analysis that uses medical and pharmacy claims data in the US from Komodo Health
Primary Outcome
Migraine-related costs included: acute and preventive migraine-related prescription costs \& drug administration costs, as well as hospitalizations, emergency room (ER) visits, outpatient visits (including urgent care), provider-office visits, and diagnostic imaging with a primary diagnosis of migraine
Interventions
- OTHER Aimovig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,839 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2020-12-31 |
What the finished NCT05177406 record still lists
NCT05177406 is an observational study that tracks outcomes without assigning an intervention. Its 1,839 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Aimovig is the first listed.
NCT05177406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05177406 about?
NCT05177406 is a clinical study titled "Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data". The proposed study is a retrospective, non-interventional analysis that uses medical and pharmacy claims data in the US from Komodo Health
What is the current status of trial NCT05177406?
This trial is currently completed. The enrollment target is 1,839 participants. The study started on 2020-08-31. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT05177406?
The interventions under investigation include: Aimovig (OTHER).
Who is sponsoring clinical trial NCT05177406?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI